Background: Saskatchewan, a Canadian Prairie province, is currently experiencing a unique HIV epidemic characterized by high rates of transmission through injection drug use. Aboriginal peoples are disproportionately affected.
Methods: We reviewed the epidemiologic and clinical characteristics of all HIV-positive individuals who attend the Regina Qu’Appelle Health Region Infectious Diseases Clinic, which serves the southern half of Saskatchewan and represents 25% of the province’s HIV burden. Molecular phylogenies were inferred from anonymized bulk HIV-1 pol sequences from pre-therapy resistance genotyping of all patients for whom testing was available. Short tip-to-tip distances (patristic distance < 0.02) between sequences from different individuals on the phylogeny were used to define clusters. Resistance data was super-imposed on phylogenetic trees to identify clusters of primary transmitted drug resistance.
Results: 415 individuals were included in the analysis. 227/415 (54.6%) were Aboriginal, 246/415 (59.2%) had injection drug use as their primary risk factor for HIV acquisition, and 243/415 (58.5%) were positive for hepatitis C antibody. Through phylogenetic analysis, a large transmission cluster of 81 individuals (19.5% of clinic) was identified in which 76 individuals were harbouring a G190A mutation in the reverse transcriptase gene, conferring NNRTI resistance. Compared to the overall clinic population, individuals with a G190A mutation in this cluster were more likely to be Aboriginal (58/76 [76.3%], RR 1.5, P < 0.01), have injection drug use as their primary risk for acquisition of HIV (63/76 [82.9%], RR 1.5, P < 0.01), and be co-infected with hepatitis C (64/76 [84.2%], RR 1.6, P < 0.01). 10 other clusters were identified but were of smaller size (≤ 18), and none were associated with transmitted drug resistance.
Conclusions: We describe a cluster of 76 individuals with primary transmitted NNRTI resistance to HIV in southern Saskatchewan, characterized by disproportionate transmission through injection drug use in Aboriginal peoples and high rates of hepatitis C co-infection. This represents a microcosm of the current provincial HIV epidemic. Similar transmission clusters are occurring elsewhere across the province, both in urban and on-reserve settings, where prevalence of injection drug use is high. These transmission dynamics, complicated further by social, cultural and geographic factors, require urgent attention and mobilization of public health and clinical resources.